Solutia PSD Delivers Innovation in Peptide Chemistry
Advertisement
Solutia Pharmaceutical Services Division (Solutia PSD) has announced the launch of its newest Centre of Excellence, Peptide chemistry. Through the application of its innovative technology, Continuous Flow Solid Phase Peptide synthesis (CFSPPS), the drug development services provider will enhance the process of producing large peptides at quantities intended for clinical and in-market use (up to 100 kg).
CFSPPS technology improves the efficiency with which peptides can be synthesized by removing many of the usual issues associated with classical solid-phase methods. "With solid-phase synthetic methods alone, we were able to produce peptides up to only eight mer. The addition of the CFSPPS process enables the production of peptides up to a size of 50 mer. In one case we were able to reduce production time for one kg of Calcitonin (a 32 mer peptide) from eight months to only six weeks. Naturally, that time savings yields a tremendous cost savings," noted Waldman.
Solutia PSD will focus on the delivery of Peptide Chemistry at its manufacturing site located in Hunzenschwil, Switzerland. There, a staff of expert chemists will specialize in a comprehensive range of peptides including natural, unnatural, cyclo, pseudo and modified peptides.
Solutia PSD's Centres of Excellence are designed to provide clients, including the world's leading pharmaceutical and biopharmaceutical companies, with access to a series of drug development services, on either an integrated or stand-alone basis. The Centres of Excellence currently include: Fast-Track Synthesis, Chromatography Services, Analytical Services, Highly Potent API Supply and Peptide Chemistry.